Summary
IDEXX Laboratories, Inc. (IDXX) announced a significant change to its Board of Directors with the election of Joseph L. (Jay) Hooley as an independent Class III Director, effective July 10, 2025. This appointment also includes his membership on the Audit Committee and Governance and Corporate Responsibility Committee. To accommodate Mr. Hooley's addition, the Board's size has been expanded from nine to ten directors, with an increase in Class III Directors from three to four. Mr. Hooley, an independent director, has no reported related party transactions with the Company. His compensation will align with that of other non-employee Directors, with prorated cash fees for the current quarter and prorated equity grants (deferred stock units or restricted stock units and stock options) to be issued on September 1, 2025. He will also be eligible to participate in the Company's Director Deferred Compensation Plan. The company issued a press release on July 10, 2025, detailing this appointment, which is furnished as an exhibit to this filing.
Key Highlights
- 1IDEXX Laboratories appointed Joseph L. (Jay) Hooley as a new independent Class III Director to its Board of Directors, effective July 10, 2025.
- 2Mr. Hooley will serve on both the Audit Committee and the Governance and Corporate Responsibility Committee.
- 3The size of the Board of Directors has been increased from nine to ten members to facilitate Mr. Hooley's appointment.
- 4There are no disclosed related-person transactions involving Mr. Hooley.
- 5Mr. Hooley will receive compensation consistent with other non-employee directors, with prorated fees and equity grants.
- 6Equity grants for Mr. Hooley will be made on September 1, 2025, and prorated for his tenure.
- 7A press release detailing Mr. Hooley's election was issued on July 10, 2025, and is included as an exhibit.